Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-07-31
2007-07-31
Sisson, Bradley L. (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C435S287200, C536S023100, C536S023500
Reexamination Certificate
active
11005029
ABSTRACT:
Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
REFERENCES:
patent: 4663318 (1987-05-01), Davis
patent: 5972614 (1999-10-01), Ruano et al.
patent: 6150354 (2000-11-01), Davis et al.
patent: 6268358 (2001-07-01), Davis et al.
patent: 6319919 (2001-11-01), Davis et al.
patent: 6323196 (2001-11-01), Kosley, Jr. et al.
patent: 6326196 (2001-12-01), Parker et al.
patent: 6358941 (2002-03-01), Snorrason et al.
patent: 6645990 (2003-11-01), Askew et al.
patent: 2003/0145343 (2003-07-01), McNeish et al.
patent: 2004/0267458 (2004-12-01), Judson et al.
patent: 2005/0048543 (2005-03-01), Aerssens et al.
patent: 2005/0250118 (2005-11-01), Aerssens et al.
patent: 2005/0260613 (2005-11-01), Aerssens et al.
patent: 2005/0277626 (2005-12-01), Dinan et al.
patent: 0 236 684 (1992-05-01), None
patent: WO 00/38686 (2000-07-01), None
patent: WO 01/80156 (2001-10-01), None
Aerssons, J., et al., “APOE genotype and response to galantamine treatment in Alzheimer's disease,”Am. J. Hum. Genet. 65:A195, Abstract 1067 (1999).
Aerssons, J., et al., “APOE Genotype: No Influence on Galantamine Treatment Efficacy Nor on Rate of Decline in Alzheimer's Disease,”Dement. Geriatr. Cogn. Disord. 12:69-77, S. Karger (2001).
Bartolucci, C., et al., “Three-dimensional Structure of a Complex of Galanthamine (Nivalin®) with Acetylcholinesterase FromTorpedo californica: Implications for the Design of New Anti-Alzheimer Drugs,”Proteins 42:182-191, Wiley-Liss, Inc. (2001).
Coyle, J. and Kershaw, P., “Galantamine, a Cholinesterase Inhibitor that Allosterically Modulates Nicotinic Receptors: Effects on the Course of Alzheimer's Disease,”Biol. Psychiatry 49:289-299, Elsevier, Inc. (2001).
Farlow, M.R., et al., “Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease,”Neurology 50:669-677, Lippincott-Raven Publishers (1998).
Hashiguchi, M., et al., “Truncation of CDK5 Activator p35 Induces Intensive Phosphorylation of Ser202/Thr205 of Human Tau,”J. Biol. Chem. 277: 44525-44530, American Society for Biochemistry and Molecular Biology (Nov. 2002).
Liu, F., et al., “Involvement of a aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3β,”FEBS Lett. 530:209-214, Elsevier Science B.V. (Oct. 2002).
Patrick, G.N., et al., Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration,Nature 402:615-622, Nature Publishing Group (1999).
Raskind, M.A., et al., “Galantamine in AD A 6-month randomized, placebo-controlled trial with a 6-month extension,”Neurology 54:2261-2268, Lippincott-Raven Publishers (2000).
Reminyl® (Galantamine HBr) Tablets and Oral Solution, Product Information Sheets, pp. 1-8, Janssen Pharmacetica Products, L.P. (2001).
Rockwood, K., et al., “Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial,”J. Neurol. Neurosurg. Psychiatry 71:589-595, BMJ Publishing Group Ltd. (2001).
Rosen, W.G., et al., “A New Rating Scale for Alzheimer's Disease,”Am. J. Psychiatry 141:1356-1364, American Psychiatric Publishing, Inc. (1984).
Samochocki, M., et al., “Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR,”Acta Neurol Scand. 176(Supp):68-73, Munksgaard International Publishers Ltd. (2000).
Scott, L.J. and Goa, K.L., “Galantamine: A Review of its Use in Alzheimer's Disease,”Drugs 60:1095-1122, Adis International Ltd. (2000).
Storch, A., et al., “Physostigmine, galanthamine and codeine act as ‘noncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cells,”Eur. J. Pharmacol. Mol. Pharmacol. Sec. 290:207-219, Elsevier Science B.V.(1995).
Tariot, P.N., et al., “A 5-month, randomized, placebo-controlled trial of galantamine in AD,”Neurology 54:2269-2276, Lippincott-Raven Publishers (2000).
Tseng, H-C., et al., “A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains,”FEBS Lett. 523:58-62, Elsevier Science B.V. (Jul. 2002).
Wilcock, G.K., et al., “Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial,”BMJ 321:1-7, BMJ Publishing Group Ltd. (2000).
Zheng, Y-I., et al., “A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells,”Eur. J. Biochem. 269:4427-4434, The Federation of European Biochemical Societies and Blackwell Publishing (Sep. 2002).
Aerssens Jeroen
Athanasiou Maria
Brain Carlos
Cohen Nadine
Dain Bradley
PGxHealth LLC
Sisson Bradley L.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
CDK5 genetic markers associated with galantamine response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CDK5 genetic markers associated with galantamine response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CDK5 genetic markers associated with galantamine response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3801372